drugset / Trial / NCT00821821
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.
Timeline
- Start
- 2009-02-28
- Primary completion
- 2010-11-30
- Completion
- 2010-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edaravone | Unknown | 1000 mg | Intravenous |
| Subject | Edaravone | Unknown | 2000 mg | Intravenous |